ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Naproxen

Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.

Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.

Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 15, 201065 company-led studies, 1 open or runningNext primary completion: Oct 29, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer240 open or runningphase 4since Apr 15, 2010Jun 5, 2008none ahead
Pfizerits history only80 open or runningphase 4since Mar 28, 2008Aug 17, 2006none ahead
GlaxoSmithKlineits history only70 open or runningphase 4since Nov 17, 2008Oct 14, 2005none ahead
Aralez Pharmaceuticalsits history only60 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Johnson & Johnsonits history only50 open or runningphase 4since Dec 2, 2005Dec 2, 2005none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 8, 2010Jan 8, 2010none ahead
Merckits history only40 open or runningphase 4since Sep 7, 2005Sep 7, 2005none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Jul 7, 2011Jul 7, 2011none ahead
Perrigoits history only20 open or runningphase 1since Dec 5, 2008Dec 5, 2008none ahead
Amgenits history only10 open or runningphase 2since Oct 19, 2012Oct 19, 2012none ahead

Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jun 5, 2008.

  1. Jul 6, 2011Phase 3 study in Pain, PostoperativeNCT01389284 · 300 enrolled · United States
  2. Aug 31, 2011Phase 3 study in PainNCT01427803 · 778 enrolled · United States
  3. Dec 16, 2011Phase 3 study in Pain, PostoperativeNCT01495858 · 267 enrolled · United States
  4. Jul 31, 2014Phase 1 study in HematologyNCT02229461 · 117 enrolled · United States
  5. Aug 17, 2015Phase 1 study in PainNCT02549469 · 32 enrolled
  6. Jan 12, 2018Phase 4 study in Pain, PostoperativeNCT03404206 · 387 enrolled · United States
  7. Feb 9, 2018Phase 4 study in DysmenorrheaNCT03448536 · 201 enrolled · United States
  8. Jun 18, 2018Phase 2 study in Osteoarthritis, KneeNCT03570554 · 41 enrolled · United States
  9. Oct 8, 2019Phase 2 study in Pain, PostoperativeNCT04132336 · 193 enrolled · United States
  10. Mar 5, 2020Phase 4 study in PainNCT04307940 · 221 enrolled · United States
  11. Jul 12, 2021Phase 2 study in Soft Tissue InjuriesNCT05026320 · 76 enrolled · Germany
  12. Jul 28, 2022Phase 3 study in ToothacheNCT05485805 · 541 enrolled · United States
  13. May 10, 2024Phase 1 study in PainNCT06415019 · 236 enrolled · United States
  14. Jul 11, 2024Phase 1 study in PainNCT06511973 · 42 enrolled · United States

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4137
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 24 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06511973Pain · United States1CompletedAug 20, 202442
NCT06415019Pain · United States1CompletedAug 1, 2024236
NCT05485805Toothache · United States3CompletedJan 25, 2024541
NCT05026320Soft Tissue Injuries · Germany2CompletedDec 20, 202176
NCT04307940Pain · United States4CompletedOct 2, 2020221
NCT04132336Pain, Postoperative · United States2CompletedMar 2, 2020193
NCT03570554Osteoarthritis, Knee · United States2CompletedJun 14, 201941
NCT03448536Dysmenorrhea · United States4CompletedSep 5, 2018201
NCT03404206Pain, Postoperative · United States4CompletedJul 6, 2018387
NCT02549469Pain1CompletedMay 200732
NCT02229461Hematology · United States1CompletedMay 2015117
NCT01495858Pain, Postoperative · United States3CompletedFeb 2012267
NCT01427803Pain · United States3CompletedDec 2011778
NCT01389284Pain, Postoperative · United States3CompletedSep 2011300
NCT01383486Pain · United States3CompletedAug 2011253
NCT01365052Pain · United States3CompletedJul 2011326
NCT01280591Pain, Postoperative · United States3CompletedJan 2011712
NCT01118273Sleep · United States4CompletedFeb 2008162
NCT00969449Pharmacokinetics · United States1CompletedMay 200928
NCT00818415Pain · United States1CompletedNov 200832
NCT00751556Healthy · United States1CompletedMar 200832
NCT00751400Pain · United States3CompletedNov 2008497
NCT00720057Toothache · United States3CompletedAug 2008312
NCT00692016Bioavailability · United States1CompletedFeb 200832

How it is read

Names in the registry

  • “Naproxen”, 17 entries
  • “PN400”, 8 entries
  • “naproxen”, 5 entries
  • “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
  • “Naproxen Sodium ER (BAYH6689)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.